Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
65
BMRN Quote, Financials, Valuation and Earnings
Last price:
$58.34
Seasonality move
:
-2.05%
Day range:
$56.82 - $58.58
52-week range:
$52.93 - $94.85
Dividend yield:
0%
P/E ratio:
21.71x
P/S ratio:
3.91x
P/B ratio:
1.93x
Volume:
1.7M
Avg. volume:
2.1M
1-year change:
-32.02%
Market cap:
$11.2B
Revenue:
$2.9B
EPS (TTM):
$2.69
Analysts' Opinion
-
Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $95.69, BioMarin Pharmaceutical has an estimated upside of 63.89% from its current price of $58.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing -11.32% downside risk from its current price of $58.39.
Fair Value
-
According to the consensus of 23 analysts, BioMarin Pharmaceutical has 63.89% upside to fair value with a price target of $95.69 per share.
BMRN vs. S&P 500
-
Over the past 5 trading days, BioMarin Pharmaceutical has underperformed the S&P 500 by -2.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioMarin Pharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioMarin Pharmaceutical has grown year-over-year revenues for 13 quarters straight. In the most recent quarter BioMarin Pharmaceutical reported revenues of $745.1M.
Earnings Growth
-
BioMarin Pharmaceutical has grown year-over-year earnings for 5 quarters straight. In the most recent quarter BioMarin Pharmaceutical reported earnings per share of $0.95.
Enterprise value:
10.5B
EV / Invested capital:
--
Price / LTM sales:
3.91x
EV / EBIT:
15.34x
EV / Revenue:
3.57x
PEG ratio (5yr expected):
0.14x
EV / Free cash flow:
16.96x
Price / Operating cash flow:
18.62x
Enterprise value / EBITDA:
13.54x
Gross Profit (TTM):
$2.3B
Return On Assets:
7.5%
Net Income Margin (TTM):
17.76%
Return On Equity:
9.62%
Return On Invested Capital:
8.4%
Operating Margin:
30.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.5B | $3B | $648.8M | $745.1M | |
| Gross Profit | $1.7B | $1.9B | $2.3B | $523.7M | $593.6M | |
| Operating Income | $88.5M | $245M | $619.6M | $78.5M | $223.9M | |
| EBITDA | $186.9M | $356.3M | $777.1M | $136.4M | $263M | |
| Diluted EPS | $0.38 | $1.07 | $2.69 | $0.46 | $0.95 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.4B | $2.8B | $3B | $3.5B | |
| Total Assets | $5.8B | $6.1B | $6.4B | $6.9B | $7.1B | |
| Current Liabilities | $430M | $490.4M | $598.2M | $1.1B | $628.2M | |
| Total Liabilities | $1.6B | $1.7B | $1.8B | $1.8B | $1.4B | |
| Total Equity | $4.2B | $4.4B | $4.7B | $5.1B | $5.8B | |
| Total Debt | $1.1B | $1.1B | $1.1B | $1.1B | $595.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $147.4M | $280.2M | $700.3M | $47M | $174.4M | |
| Cash From Investing | -$137.8M | -$95.5M | $122.5M | -$14.2M | -$28.2M | |
| Cash From Financing | -$34.1M | -$20.8M | -$522.4M | -$42.8M | -$38.8M | |
| Free Cash Flow | $21.8M | $163.2M | $620.2M | $12.9M | $157.6M | |
BMRN
Sector
Market Cap
$11.2B
$34.4M
Price % of 52-Week High
61.56%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-32.02%
-37.36%
Beta (5-Year)
0.168
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$58.15
200-day SMA
Sell
Level
$64.09
Bollinger Bands (100)
Sell
Level
56 - 67.88
Chaikin Money Flow
Buy
Level
164.3M
20-day SMA
Buy
Level
$56.42
Relative Strength Index (RSI14)
Buy
Level
55.47
ADX Line
Buy
Level
18.51
Williams %R
Neutral
Level
-25.5627
50-day SMA
Buy
Level
$57.50
MACD (12, 26)
Buy
Level
0.28
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
246.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.7343)
Buy
CA Score
(Annual)
Level (1.2841)
Buy
Beneish M-Score
(Annual)
Level (-2.424)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.8579)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Stock Forecast FAQ
In the current month, BMRN has received 17 Buy ratings 6 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $95.69.
-
Where Will BioMarin Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioMarin Pharmaceutical share price will rise to $95.69 per share over the next 12 months.
-
What Do Analysts Say About BioMarin Pharmaceutical?
Analysts are divided on their view about BioMarin Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioMarin Pharmaceutical is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is BioMarin Pharmaceutical's Price Target?
The price target for BioMarin Pharmaceutical over the next 1-year time period is forecast to be $95.69 according to 23 Wall Street analysts, 17 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is BMRN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioMarin Pharmaceutical is a Buy. 17 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BMRN?
You can purchase shares of BioMarin Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioMarin Pharmaceutical shares.
-
What Is The BioMarin Pharmaceutical Share Price Today?
BioMarin Pharmaceutical was last trading at $58.34 per share. This represents the most recent stock quote for BioMarin Pharmaceutical. Yesterday, BioMarin Pharmaceutical closed at $58.39 per share.
-
How To Buy BioMarin Pharmaceutical Stock Online?
In order to purchase BioMarin Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
